Literature DB >> 30952064

Extracellular ATP activates P2X7R-NF-κB (p65) pathway to promote the maturation of bone marrow-derived dendritic cells of mice.

Ying Yu1, Songfu Feng1, Shiyu Wei2, Yanyan Zhong1, Guoguo Yi1, Haiyan Chen1, Lifang Liang1, Hui Chen1, Xiaohe Lu3.   

Abstract

The maturation state of dendritic cell (DC) plays an important role in immune activities. Previously we had found that NF-κB (p65) pathway could promote DC maturation and subsequent immune effects. But the upstream mechanism of this pathway was still unclear. Extracellular adenosine triphosphate (ATP) activating its receptor P2X7R has recently been considered as the fourth signal to activate T lymphocytes. Here we aimed to find out the connection between P2X7R and NF-κB (p65) pathway in DC maturation. Results showed that the expression of P2X7R and the intracellular ATP levels were increased along with the maturation of DC. P2X7R agonist stimulated the morphological changes of DCs into the appearance of mature DCs, and promoted the expression of NF-κB (p65), as well as the release of IFN-γ and IL-12. Whereas, P2X7R inhibitor had the opposite influences. Co-immunoprecipitation assay confirmed the binding of P2X7R and NF-κB (p65). Our study suggested that extracellular ATP could promote DC maturation and release of inflammatory cytokines through the binding of P2X7R and NF-κB (p65). This is the first study to show the P2X7R-NF-κB (p65) pathway in DC. Interference with this pathway may be able to regulate immune responses in areas like infectious diseases, inflammation, transplantation, tumor and autoimmune diseases. In addition, intracellular ATP level could be a new indicator of the maturation state of DC.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ATP; Dendritic cell; Maturation; NF-κB; P2X7R

Year:  2019        PMID: 30952064     DOI: 10.1016/j.cyto.2019.03.019

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Trichostatin A inhibits dendritic cell maturation through down-regulating NF-κ B (p65) pathway.

Authors:  Ying Yu; Bing Liu; Siyan Chen; Jianxun Wang; Feng Chen; Tian Liu; Nan Jiang; Wensi Chen; Shengbei Weng; Xiaoxiao Cai; Daoman Xiang
Journal:  Mol Biol Rep       Date:  2022-01-14       Impact factor: 2.316

2.  Astaxanthin Attenuates Neuroinflammation in Status Epilepticus Rats by Regulating the ATP-P2X7R Signal.

Authors:  Ming Wang; Xiaolin Deng; Yangmei Xie; Yinghui Chen
Journal:  Drug Des Devel Ther       Date:  2020-04-30       Impact factor: 4.162

3.  TRIP6 regulates the proliferation, migration, invasion and apoptosis of osteosarcoma cells by activating the NF-κB signaling pathway.

Authors:  Wei Liu; Li Cheng; Qingning Li; Juehua Jing
Journal:  Exp Ther Med       Date:  2020-01-22       Impact factor: 2.447

4.  Toll-Like Receptor-Mediated Activation of CD39 Internalization in BMDCs Leads to Extracellular ATP Accumulation and Facilitates P2X7 Receptor Activation.

Authors:  Ronglan Zhao; Jinjuan Qiao; Xumei Zhang; Yansong Zhao; Xiangying Meng; Deming Sun; Xiaoxiang Peng
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

Review 5.  P2X7 Receptor at the Crossroads of T Cell Fate.

Authors:  Elizabeth Rivas-Yáñez; Carlos Barrera-Avalos; Brian Parra-Tello; Pedro Briceño; Mariana V Rosemblatt; Juan Saavedra-Almarza; Mario Rosemblatt; Claudio Acuña-Castillo; María Rosa Bono; Daniela Sauma
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  By Regulating the NLRP3 Inflammasome Can Reduce the Release of Inflammatory Factors in the Co-Culture Model of Tuberculosis H37Ra Strain and Rat Microglia.

Authors:  Zhen Xie; Hao Hui; Qian Yao; Yan Duan; Wu Li; Ye Cheng; Meng Zhang; Ye Tian; Gang Zhao
Journal:  Front Cell Infect Microbiol       Date:  2021-04-13       Impact factor: 5.293

Review 7.  Mitochondrial-derived damage-associated molecular patterns amplify neuroinflammation in neurodegenerative diseases.

Authors:  Miao-Miao Lin; Na Liu; Zheng-Hong Qin; Yan Wang
Journal:  Acta Pharmacol Sin       Date:  2022-03-01       Impact factor: 7.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.